And what do you think about companies that perform large-scale medical analysis on genomic data of customers, and keep their research behind closed doors?
(Probably not a big issue right now, but it could be in the future).
Well, they are the ones funding the research teams and equipment, so it's a different scenario IMHO.
I think we can agree though that knowledge should converge into being easily accessible, all while reducing the collateral effects of doing so (as the article explains: tenure, promotions, prestige…).
(Probably not a big issue right now, but it could be in the future).